This may also explain why conventional tissue biomarkers of response to ICIs, such as PD-L1 expression, have little to no predictive value in CCA and are therefore not recommended for selecting patients for chemoimmunotherapy in clinical practice. This evidence concerns the gene CD274 and cholangiocarcinoma.